Abstract Details
|
Adam J. Margolius, MD
(Cleveland Clinic)
PRESENTER |
Dr. Margolius has nothing to disclose. |
| Fernando Cubillos | Mr. Cubillos has nothing to disclose. |
| No disclosure on file | |
| Peter Schmidt, MD (NIMH/NIH) | No disclosure on file |
| Tanya Simuni, MD, FAAN (Northwestern University Feinberg School of Medicien) | Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for cadia, AcureX, Adamas, AskBio, Amneal, Blue Rock Therapeutics, Caraway Therapeutics, Critical Path for Parkinson's Consortium (CPP), Denali, Michael J Fox Foundation, Neuroderm, Sanofi, Sinopia, Roche, Takeda and Vanqua Bio. Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for of Koneksa, Neuroderm, Sanofi, UCB, AcureX, Adamas, AskBio, Biohaven, Denali, GAIN, Neuron23 and Roche. Dr. Simuni has received research support from Amneal, Biogen, Neuroderm, Prevail, Roche, and UCB and an investigator for NINDS, MJFF, Parkinson's Foundation. |